Dihydroxy fatty acids can be used for screening autism traits in toddlers

Polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA), are key regulators of inflammation via their metabolism by cytochrome P450 (CYP) and soluble epoxide hydrolase.1, 2 In pregnant mice exposed to high-dose glyphosate during gestation and lactation, offspring exhibit autism spectrum disorder (ASD)-like behaviors accompanied by reduced AA-derived epoxy fatty acids in plasma and multiple brain regions.3 AA-derived dihydroxy fatty acids in umbilical cord blood have been associated with ASD symptoms at 6 years of age, especially in girls.4 As umbilical cord blood reflects the fetal period, whether abnormalities in CYP–PUFA metabolism persist into early childhood remains unclear. Given the early onset and developmental trajectory of ASD symptoms, we investigated the relationship between CYP–PUFA metabolites (epoxy fatty acids and dihydroxy fatty acids) in peripheral blood and autistic traits during early childhood. We included 19 toddlers with ASD (mean age, 3.9 years; standard deviation [SD], 0.7) and 21 typically developing (TD) toddlers (mean age, 4.5 years; SD, 1.4). Among the 40 participants, 23 were boys, and 17 were girls (Table S1). We first examined the association between CYP–PUFA metabolites and the Autism Spectrum Quotient–Child (AQ), to identify candidates for subsequent receiver operating characteristic (ROC) analysis. A significant association was found exclusively with 14,15-diHETrE, a dihydroxy fatty acid derived from AA (β = −0.368; 95% confidence interval [CI], −0.112 to −0.010; p = 0.021; Table S2). In contrast, no significant associations were observed with metabolites derived from linoleic acid, eicosapentaenoic acid, or docosahexaenoic acid. We then performed sex-stratified analyses, adjusting for the developmental quotient, which is a potential confounding factor that affects autistic traits. Figure 1a presents scatter plots and regression lines showing the relationships between AA-derived dihydroxy fatty acids and AQ scores. Both 11,12- and 14,15-diHETrE were significantly associated with autistic traits in girls (β = −0.455; 95% CI, −0.131 to −0.014; p = 0.019; β = −0.715; 95% CI, −0.153 to −0.031; p = 0.006, respectively; Table S2). Only dihydroxy fatty acids derived from AA among PUFA influenced autistic traits, specifically in girls, supporting our previous cord blood report.4 Notably, lower levels of these metabolites were associated with increased autistic traits. Either a decrease or an increase in AA-derived dihydroxy fatty acids in umbilical cord blood may be related to ASD.4, 5 Such metabolic imbalances may persist beyond the fetal period and influence ASD pathophysiology via inflammatory pathways. Importantly, although AA-derived dihydroxy fatty acids are generally pro-inflammatory, certain subtypes can exert anti-inflammatory effects under specific conditions.1, 6 These contrasting roles suggest that reductions in specific diHETrEs could disturb the inflammatory–anti-inflammatory balance, potentially affecting early neurodevelopment relevant to ASD. We next assessed the potential of AA-derived dihydroxy fatty acids as biomarkers for ASD using ROC analysis. Among them, 8,9-diHETrE emerged as the most promising single candidate. At an optimal cutoff point of 174.8 pg/mL, it achieved a sensitivity of 92.3%, specificity of 70%, and an AUC of 0.792 (p = 0.0003; Figure 1c and Table S3), outperforming other isomers. This high sensitivity captured 12 of 13 ASD cases. Although six TD toddlers were also classified as positive, this likely reflects a heightened sensitivity to early ASD-related metabolic shifts. The discriminative pattern was particularly evident in younger participants (Figure 1b), suggesting its promise as an early screening biomarker. We further evaluated a composite biomarker combining four AA-derived isomers: 5,6-, 8,9-, 11,12-, and 14,15-diHETrE. The combined score achieved an AUC of 0.886 at a cutoff value of 0.526 (p = 0.0001; sensitivity = 71.4%, specificity = 100%; Figure 1c and Table S3). Importantly, although two of seven ASD cases were not identified, all TD toddlers were correctly classified (Figure 1c), demonstrating excellent specificity and overall classification performance. Although the small sample size warrants cautious interpretation, the clear discriminative patterns underscore the potential utility of AA-derived diHETrEs as clinically relevant biomarkers. Given the limited number of ASD cases relative to the number of predictors, this model may be affected by overfitting, and its estimated diagnostic performance should be interpreted with caution. These findings are based on blood samples obtained during early childhood, a developmental stage in which biomarker data remain scarce due to the challenges of sample collection. Current diagnostic practices for ASD rely largely on the accumulation of behavioral features over time, which may lead to diagnostic delays or reduced consistency, particularly in early childhood.7 Early diagnosis is widely recognized as critical for improving long-term outcomes in individuals with ASD because it enables timely access to appropriate interventions and support services.8 Moreover, interventions delivered during sensitive periods of brain development normalize neural activity patterns and improve behavioral outcomes.9 However, several limitations should be considered. ASD and TD toddlers were recruited from different regions in Japan, and the influence of regional factors, including dietary patterns, cannot be completely excluded, as dietary intake can modulate PUFA profiles and their downstream metabolites.10 Although sample collection procedures and storage conditions were standardized, slight variations in storage duration may have influenced the quantification of CYP–PUFA metabolites. In addition, although the validated age range of the Japanese AQ is 6–15 years, it was also applied in some participants younger than this range (Table S1), which should be considered while interpreting the findings. Further validation in larger-scale studies is needed to confirm their diagnostic value and generalizability. Nonetheless, our results highlight the feasibility and promise of implementing biomarker-based screening, even in toddlers. Hideo Matsuzaki conceived and organized this study. Takaharu Hirai analyzed the data and drafted the manuscript. Toru Fujioka, Keisuke Wakusawa, Takahiro Nara, and Kenji J. Tsuchiya provided investigation and resources. Takayo Ohto-Nakanishi performed the LC-MS/MS analysis. Naoko Umeda analyzed and interpreted the data. All authors contributed to the discussion of the results and the creation of this manuscript. We are grateful to the individuals who participated in the study. We thank Ms. Fumiho Yamamoto and Ms. Natsuki Miyagoshi for technical assistance, Ms. Tomoko Taniguchi for clerical support, and Hiroki Nakanishi, PhD, from Lipidome Lab for providing technical advice for this study. This work was supported, in part, by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Early-Career Scientists to T.H. (23K16415) and a Grant-in-Aid for Scientific Research (B) to H.M. (23K27527). T.O.-N. is employed with Lipidome Lab Co., Ltd. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. All procedures were approved by the ethics committee of the University of Fukui and the Hamamatsu University School of Medicine, and were conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the Ministry of Health, Labour and Welfare of Japan. All participants were given a complete description of the study and provided written informed consent from their parent and/or legal guardian before enrollment. N/A. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Authors

Institutions

Publication Details

Journal
Psychiatry and Clinical Neurosciences Reports
Published
2026-04-20
DOI
https://doi.org/10.1002/pcn5.70338
Primary Topic
Eicosanoids and Hypertension Pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dihydroxy fatty acids can be used for screening autism traits in toddlers

Toru Fujioka, Naoko Umeda, Kenji J. Tsuchiya, T. Hirai et al.
Psychiatry and Clinical Neurosciences Reports
Eicosanoids and Hypertension Pharmacology
article

Dihydroxy fatty acids can be used for screening autism traits in toddlers

Toru Fujioka, Naoko Umeda, Kenji J. Tsuchiya, T. Hirai, Keisuke Wakusawa, Takayo Ohto‐Nakanishi, Hideo Matsuzaki, Takahiro Nara
article en

Abstract

Polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA), are key regulators of inflammation via their metabolism by cytochrome P450 (CYP) and soluble epoxide hydrolase.1, 2 In pregnant mice exposed to high-dose glyphosate during gestation and lactation, offspring exhibit autism spectrum disorder (ASD)-like behaviors accompanied by reduced AA-derived epoxy fatty acids in plasma and multiple brain regions.3 AA-derived dihydroxy fatty acids in umbilical cord blood have been associated with ASD symptoms at 6 years of age, especially in girls.4 As umbilical cord blood reflects the fetal period, whether abnormalities in CYP–PUFA metabolism persist into early childhood remains unclear. Given the early onset and developmental trajectory of ASD symptoms, we investigated the relationship between CYP–PUFA metabolites (epoxy fatty acids and dihydroxy fatty acids) in peripheral blood and autistic traits during early childhood. We included 19 toddlers with ASD (mean age, 3.9 years; standard deviation [SD], 0.7) and 21 typically developing (TD) toddlers (mean age, 4.5 years; SD, 1.4). Among the 40 participants, 23 were boys, and 17 were girls (Table S1). We first examined the association between CYP–PUFA metabolites and the Autism Spectrum Quotient–Child (AQ), to identify candidates for subsequent receiver operating characteristic (ROC) analysis. A significant association was found exclusively with 14,15-diHETrE, a dihydroxy fatty acid derived from AA (β = −0.368; 95% confidence interval [CI], −0.112 to −0.010; p = 0.021; Table S2). In contrast, no significant associations were observed with metabolites derived from linoleic acid, eicosapentaenoic acid, or docosahexaenoic acid. We then performed sex-stratified analyses, adjusting for the developmental quotient, which is a potential confounding factor that affects autistic traits. Figure 1a presents scatter plots and regression lines showing the relationships between AA-derived dihydroxy fatty acids and AQ scores. Both 11,12- and 14,15-diHETrE were significantly associated with autistic traits in girls (β = −0.455; 95% CI, −0.131 to −0.014; p = 0.019; β = −0.715; 95% CI, −0.153 to −0.031; p = 0.006, respectively; Table S2). Only dihydroxy fatty acids derived from AA among PUFA influenced autistic traits, specifically in girls, supporting our previous cord blood report.4 Notably, lower levels of these metabolites were associated with increased autistic traits. Either a decrease or an increase in AA-derived dihydroxy fatty acids in umbilical cord blood may be related to ASD.4, 5 Such metabolic imbalances may persist beyond the fetal period and influence ASD pathophysiology via inflammatory pathways. Importantly, although AA-derived dihydroxy fatty acids are generally pro-inflammatory, certain subtypes can exert anti-inflammatory effects under specific conditions.1, 6 These contrasting roles suggest that reductions in specific diHETrEs could disturb the inflammatory–anti-inflammatory balance, potentially affecting early neurodevelopment relevant to ASD. We next assessed the potential of AA-derived dihydroxy fatty acids as biomarkers for ASD using ROC analysis. Among them, 8,9-diHETrE emerged as the most promising single candidate. At an optimal cutoff point of 174.8 pg/mL, it achieved a sensitivity of 92.3%, specificity of 70%, and an AUC of 0.792 (p = 0.0003; Figure 1c and Table S3), outperforming other isomers. This high sensitivity captured 12 of 13 ASD cases. Although six TD toddlers were also classified as positive, this likely reflects a heightened sensitivity to early ASD-related metabolic shifts. The discriminative pattern was particularly evident in younger participants (Figure 1b), suggesting its promise as an early screening biomarker. We further evaluated a composite biomarker combining four AA-derived isomers: 5,6-, 8,9-, 11,12-, and 14,15-diHETrE. The combined score achieved an AUC of 0.886 at a cutoff value of 0.526 (p = 0.0001; sensitivity = 71.4%, specificity = 100%; Figure 1c and Table S3). Importantly, although two of seven ASD cases were not identified, all TD toddlers were correctly classified (Figure 1c), demonstrating excellent specificity and overall classification performance. Although the small sample size warrants cautious interpretation, the clear discriminative patterns underscore the potential utility of AA-derived diHETrEs as clinically relevant biomarkers. Given the limited number of ASD cases relative to the number of predictors, this model may be affected by overfitting, and its estimated diagnostic performance should be interpreted with caution. These findings are based on blood samples obtained during early childhood, a developmental stage in which biomarker data remain scarce due to the challenges of sample collection. Current diagnostic practices for ASD rely largely on the accumulation of behavioral features over time, which may lead to diagnostic delays or reduced consistency, particularly in early childhood.7 Early diagnosis is widely recognized as critical for improving long-term outcomes in individuals with ASD because it enables timely access to appropriate interventions and support services.8 Moreover, interventions delivered during sensitive periods of brain development normalize neural activity patterns and improve behavioral outcomes.9 However, several limitations should be considered. ASD and TD toddlers were recruited from different regions in Japan, and the influence of regional factors, including dietary patterns, cannot be completely excluded, as dietary intake can modulate PUFA profiles and their downstream metabolites.10 Although sample collection procedures and storage conditions were standardized, slight variations in storage duration may have influenced the quantification of CYP–PUFA metabolites. In addition, although the validated age range of the Japanese AQ is 6–15 years, it was also applied in some participants younger than this range (Table S1), which should be considered while interpreting the findings. Further validation in larger-scale studies is needed to confirm their diagnostic value and generalizability. Nonetheless, our results highlight the feasibility and promise of implementing biomarker-based screening, even in toddlers. Hideo Matsuzaki conceived and organized this study. Takaharu Hirai analyzed the data and drafted the manuscript. Toru Fujioka, Keisuke Wakusawa, Takahiro Nara, and Kenji J. Tsuchiya provided investigation and resources. Takayo Ohto-Nakanishi performed the LC-MS/MS analysis. Naoko Umeda analyzed and interpreted the data. All authors contributed to the discussion of the results and the creation of this manuscript. We are grateful to the individuals who participated in the study. We thank Ms. Fumiho Yamamoto and Ms. Natsuki Miyagoshi for technical assistance, Ms. Tomoko Taniguchi for clerical support, and Hiroki Nakanishi, PhD, from Lipidome Lab for providing technical advice for this study. This work was supported, in part, by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Early-Career Scientists to T.H. (23K16415) and a Grant-in-Aid for Scientific Research (B) to H.M. (23K27527). T.O.-N. is employed with Lipidome Lab Co., Ltd. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. All procedures were approved by the ethics committee of the University of Fukui and the Hamamatsu University School of Medicine, and were conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the Ministry of Health, Labour and Welfare of Japan. All participants were given a complete description of the study and provided written informed consent from their parent and/or legal guardian before enrollment. N/A. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Psychiatry and Clinical Neurosciences ReportsVol. 5(2)
University of Fukui (JP), Fukui University of Technology (JP), Hamamatsu University School of Medicine (JP), Miyagi Children's Hospital (JP), University of Fukui Hospital (JP), Akita University of Art (JP), The University of Osaka (JP)
Good health and well-being
Openalex Percentile: Top 9%
Eicosanoids and Hypertension Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.